Linagliptin-associated bullous pemphigoid treated with rituximab

Dipeptidyl peptidase 4 (DPP-4) inhibitors are increasingly used these days in management of diabetes. There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP). We report a case of association between linagliptin use and BP and su...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Case Rep
Hlavní autoři: Mani, Hariharasudan, Safo, Patrick, Onitilo, Adedayo A
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2019
Témata:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768351/
https://ncbi.nlm.nih.gov/pubmed/31570343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-229902
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky